Novogen (NVGN) Promising Data in Brain Cancer; eFuture Information Technology (EFUT) and …

Novogen Limited (NVGN)

Shares of Novogen Limited (NVGN) touched an increase in value of more than 50% in extended-hours trading on Tuesday, after the company confirmed that its TRXE-009 is showing the potential to become an important new therapy in the fight against adult and pediatric brain cancer, based on findings from studies conducted at the Feinstein Institute for Medical Research, the research branch of North Shore-LIJ Health System.

The latest study looked at the ability of NVGN's TRXE-009 to kill a library of patient-derived cell cultures from subjects with glioblastoma multiform (GBM). These stemlike cancer cells are believed to be responsible for chemotherapy resistance and tumor recurrence, so killing these highly resistant GBM cancer stem cell is considered to be a fundamental requirement to successfully treating this highly destructive diseas

According to NVGN, all patient derived cancer cells represented in the library responded to TRXE-009 at clinically relevant doses, suggesting a strong therapeutic potential.

These findings, together with other results from recently announced pre-clinical studies, suggest that NVGN's TRXE-009 is a unique drug candidate in preferentially targeting tumors with a common embryonic origin in neural/neural crest cells.

NVGN is engaged in the pharmaceutical research and development business in Australia. NVGN group includes US-based CanTx Inc, a joint venture company with Yale University

More about Novogen Limited (NVGN) at http://www.novogen.com

**

eFuture Information Technology Inc. (EFUT)

Read more:
Novogen (NVGN) Promising Data in Brain Cancer; eFuture Information Technology (EFUT) and ...